Treatment and inhibition of disease conditions using flexible heteroarotinoids

Abstract

The present invention contemplates methods of treating, reducing, inhibiting or preventing several diseases by the administration of flexible heteroarotinoids. Among the diseases or conditions which can benefit from treatment with flexible heteroarotinoids as described herein are, (1) cancers and other diseases that involve abnormal differentiation, (2) diabetes, (3) hemophelia, (4) liver disease, (5) diseases involving human aldehyde dehydrogenase 2, (6) polycystic kidney disease, (7) lysosomal storage diseases, (8) high cholesterol, (9) obesity, (10) high triglycerides, (11) glycoprotein metabolism diseases, and (12) diseases involving abnormal angiogenesis.

1 . A method for treating or inhibiting polycystic kidney disease in a subject in need of treatment thereof or at risk therefor, comprising:
 providing a quantity of a flexible heteroarotinoid having a urea or thiourea linker; and   administering the flexible heteroarotinoid to the subject.   
   
   
       2 . The method of  claim 1  wherein the subject is a mammal. 
   
   
       3 . The method of  claim 1  wherein the subject is a human. 
   
   
       4 . The method of  claim 1  wherein the flexible heteroarotinoid is selected from the group consisting of SHetA2, SHetA3, and SHetA4. 
   
   
       5 . The method of  claim 1  wherein the flexible heteroarotinoid is provided in a composition comprising a pharmaceutically-acceptable carrier. 
   
   
       6 . A method for treating or inhibiting a lysosomal storage disease in a subject in need of such treatment, comprising:
 providing a quantity of a flexible heteroarotinoid having a urea or thiourea linker; and   administering the flexible heteroarotinoid to the subject.   
   
   
       7 . The method of  claim 6  wherein the lysosomal storage disease is selected from the group consisting of Batten disease, Fabry disease, Gaucher disease, Krabbe disease, Mucopolysacchiradosis I (MPS I/Hurler/Hurler-Scheie/Scheie), Mucopolysacchiradosis II (MPS II/Hunter Disease), Niemann-Pick disease, Pompe disease, and Tay-Sachs disease. 
   
   
       8 . The method of  claim 6  wherein the subject is a mammal. 
   
   
       9 . The method of  claim 6  wherein the subject is a human. 
   
   
       10 . The method of  claim 6  wherein the flexible heteroarotinoid is selected from the group consisting of SHetA2, SHetA3, and SHetA4. 
   
   
       11 . The method of  claim 6  wherein the flexible heteroarotinoid is provided in a composition comprising a pharmaceutically-acceptable carrier.